CorMedix Inc. (CRMD) Stock

CorMedix Inc. is a pioneering biopharmaceutical company dedicated to advancing therapeutic products aimed at preventing and treating infectious and inflammatory diseases globally. Central to its innovative portfolio is DefenCath/Neutrolin, a groundbreaking anti-infective solution specifically designed to reduce and prevent catheter-related infections and thrombosis in patients requiring central venous catheters across various clinical settings, including hemodialysis, total parenteral nutrition, and oncology.

Formerly known as Picton Holding Company, Inc., CorMedix, Inc. underwent a name change in January 2007 to reflect its focused mission in the biopharmaceutical sector. Since its inception in 2006, the company has been headquartered in Berkeley Heights, New Jersey, strategically positioning itself at the nexus of innovation and therapeutic advancement in the healthcare industry.

With a commitment to addressing critical medical needs through cutting-edge research and development, CorMedix Inc. continues to expand its footprint in the field of infectious and inflammatory diseases. Leveraging its expertise, the company aims to deliver transformative solutions that improve patient outcomes and quality of life on a global scale.

Driven by a vision to redefine treatment paradigms, CorMedix Inc. remains steadfast in its pursuit of developing novel therapies that set new standards in healthcare. Through strategic initiatives and ongoing clinical advancements, the company strives to make a meaningful impact in the lives of patients worldwide.